Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2013 | 11 | 1 | 9–23

Article title

Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące nabłonkowych nowotworów jajnika: raka jajnika oraz guzów o granicznej złośliwości


Title variants

Recommendations of Polish Gynecological Oncology Society concerning epithelial tumors of the ovary: ovarian cancer and borderline tumors

Languages of publication












Physical description


  • Klinika Onkologii, Uniwersytet Medyczny w Poznaniu, ul. Szamarzewskiego 82/84, 61-569 Poznań
  • Katedra i Klinika Onkologii Ginekologicznej, Uniwersytet Medyczny we Wrocławiu, pl. Hirszfelda 12, 53-413 Wrocław
  • Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie, ul. Garncarska 11, 31-115 Kraków
  • Klinika Ginekologii Operacyjnej, Uniwersytet Medyczny w Poznaniu, ul. Polna 33, 60-535 Poznań
  • Klinika Ginekologii i Onkologii, Szpital Uniwersytecki w Krakowie, ul. Kopernika 23, 31-501 Kraków
  • Dział Kliniczny Ginekologii Onkologicznej, Świętokrzyskie Centrum Onkologii, ul. Artwińskiego 3, 25-734 Kielce
  • Oddział Ginekologiczno-Położniczy, Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku, ul. Mickiewicza 12, 76-270 Ustka
  • I Katedra i Klinika Ginekologii i Położnictwa, Akademia Medyczna im. Piastów Śląskich, ul. T. Chałubińskiego 3, 50-368 Wrocław
  • Oddział Ginekologii Onkologicznej, Ogólnej i Położnictwa, Samodzielny Publiczny ZOZ Okręgowy Szpital Kolejowy w Katowicach, ul. Panewnicka 65, 40-760 Katowice
  • Katedra i Oddział Kliniczny Ginekologii, Położnictwa i Ginekologii Onkologicznej, Szpital Specjalistyczny nr 2 w Bytomiu, ul. Stefana Batorego 15, 41-902 Bytom
  • I Katedra i Klinika Położnictwa i Ginekologii WUM, ul. Starynkiewicza 1/3, 02-015 Warszawa
  • Oddział Radioterapii i Onkologii Ginekologicznej, Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie, ul. Garbary 15, 61-866 Poznań
  • Oddział Kliniczny Ginekologii i Położnictwa, Wojewódzki Szpital Specjalistyczny im. Fryderyka Chopina w Rzeszowie, ul. Chopina 2, 35-055 Rzeszów
  • Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie, ul. Garncarska 11, 31-115 Kraków
  • Klinika Onkologii, Uniwersytet Medyczny w Poznaniu, ul. Szamarzewskiego 82/84, 61-569 Poznań


  • Aghajanian C., Blank S.V., Goff B.A. i wsp.: OCEANS: a random­ized, double-blind, placebo-controlled phase III trial of che­motherapy with or without bevacizumab in patients with plat­inum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012; 30: 2039–2045.
  • Armstrong D.K., Bundy B., Wenzel L. i wsp.: Intraperitoneal cispla­tin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354: 34–43.
  • Calvert A.H., Newell D.R., Gumbrell L.A. i wsp.: Carboplatin dos­age: Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 1989; 7: 1748–1756.
  • Chi D.S., McCaughty K., Diaz J.P. i wsp.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933–1939.
  • De Gregorio N., Baumann K.H., Keyver-Paik M.D. i wsp.: Outcome of patients with borderline ovarian tumors: Results of the mul­ticenter AGO ROBOT study. J. Clin. Oncol. 2012; 30 (supl.; abstr. 5005).
  • du Bois A., Reuss A., Pujade-Lauraine E. i wsp.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively ran­domized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244.
  • Eisenhauer E.A, Therasse P., Bogaerts J. i wsp.: New response evaluation criteria in solid tumours: Revised RECIST guide­line (version 1.1). Eur. J. Cancer 2009; 45: 228–247.
  • Ferrandina G., Ludovisi M., Lorusso D. i wsp.: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 2008; 26: 890–896.
  • Goff B.A., Matthews B., Andrilla C.H. i wsp.: How are symptoms of ovarian cancer managed? A study of primary care physi­cians. Cancer 2011; 117: 4414–4423.
  • Gordon A.N., Fleagle J.T., Guthrie D. i wsp.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylat­ed liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001; 19: 3312–3322.
  • Harter P., Hilpert F., Mahner S. i wsp.: Prognostic factors for com­plete debulking in first- and second-line ovarian cancer. Int. J. Gynecol. Cancer 2009; 19: S14–S17.
  • Harter P., Sehouli J., Reuss A. i wsp.: Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO-OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 2011; 21: 289–295.
  • Heintz A.P., Odicino F., Maisonneuve P. i wsp.: Carcinoma of the ovary. Figo 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynecol. Obstet. 2006; 95 supl. 1: S161–S163.
  • Katsumata N., Yasuda M., Takahashi F. i wsp.: Dose-dense pacl­itaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331–1338.
  • Kauff N.D., Satagopan J.M., Robson M.E. i wsp.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2002; 346: 1609–1615.
  • Kehoe S., Hook J., Nankivell M. i wsp.: Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. J. Clin. Oncol. 2013; 31 (supl.; abstr. 5500).
  • Markman M., Blessing J., Rubin S.C. i wsp.: Phase II trial of week­ly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncol­ogy Group study. Gynecol. Oncol. 2006; 101: 436–440.
  • Markman M., Liu P.Y., Wilczynski S. i wsp.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to plati­num and paclitaxel-based chemotherapy: a Southwest Oncolo­gy Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003; 21: 2460–2465.
  • McGuire W.P., Hoskins W.J., Brady M.F. i wsp.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996; 334: 1–6.
  • Oksefjell H., Sandstad B., Tropé C.: The role of secondary cytore­duction in the management of the first relapse in epithelial ovarian cancer. Ann. Oncol. 2009; 20: 286–293.
  • Onda T., Yoshikawa H., Yasugi T. i wsp.: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br. J. Cancer 2005; 92: 1026–1032.
  • Ozols R.F., Bundy B.N., Greer B.E. i wsp.: Phase III trial of carbo­platin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003; 21: 3194–3200.
  • Parmar M.K., Ledermann J.A., Colombo N. i wsp.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum based chemotherapy in women with relapsed ovar­ian cancer: the ICON4/AGO-OVAR-2-2 trial. Lancet 2003; 361: 2099–2106.
  • Perren T., Swart A.C., Pfisterer J. i wsp.: A phase 3 trial of bevacizum­ab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484–2496.
  • Pfisterer J., Plante M., Vergote I. i wsp.: Gemcitabine plus carbopla­tin compared with carboplatin in patients with platinum-sensi­tive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 2006; 24: 4699–4707.
  • Pignata S., Scambia G., Rossella Lauria R. i wsp.: A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) – European Network of Gynaeco­logical Oncological Trial Groups (ENGOT-ov-10) and Gyne­cologic Cancer Intergroup (GCIG) trial. J. Clin. Oncol. 2013; 31 (supl.; abstr. LBA5501).
  • Pujade-Lauraine E., Hilpert F., Weber B. i wsp.: AURELIA: A ran­domized phase III trial evaluating bevacizumab plus chemo­therapy for platinum-resistant recurrent ovarian cancer. J. Clin. Oncol. 2012; 30 (supl.; abstr. LBA5002).
  • Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E. i wsp.: Pegylated liposomal Doxorubicin and Carboplatin compared with paclitaxel and carboplatin for patients with platinum-sen­sitive ovarian cancer in late relapse. J. Clin. Oncol. 2010; 28: 3323–3329.
  • Rebbeck T.R., Lynch H.T., Neuhausen S.L.: Prophylactic oophorec­tomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002; 346: 1616–1622.
  • Rose P.G., Nerenstone S., Brady M.F. i wsp.: Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 2004; 351: 2489–2497.
  • Rustin G., van der Burg M., Griffin C. i wsp.: Early versus delayed treatment of relapsed ovarian cancer. Lancet 2011; 377: 380–381. ten Bokkel Huinink W., Gore M., Carmichael J. i wsp.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovar­ian cancer. J. Clin. Oncol. 1997; 15: 2183–2193.
  • Therasse P., Arbuck S.G., Eisenhauer E.A. i wsp.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Insti­tute of Canada. J. Natl Cancer Inst. 2000; 92: 205–216.
  • Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory zło­śliwe w Polsce w 2010 roku. Centrum Onkologii – Instytut M. Skłodowskiej-Curie, Warszawa 2012. Dostęp elektronicz­ny: http://www.onkologia.org.pl/doc/Nowotw2010.pdf.
  • van der Burg M.E., van Lent M., Buyse M. i wsp.: The effect of debulking surgery after induction chemotherapy on the prog­nosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 1995; 332: 629–634.
  • Vasey P.A., Jayson G.C., Gordon A. i wsp.: Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 2004; 96: 1682–1691.
  • Vergote I., Tropé C.G., Amant F. i wsp.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010; 363: 943–953.

Document Type


Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.